Avinger Inc Stock Price, News & Analysis

Avinger, Inc. (NASDAQ:AVGR) has been granted an extension until May 19, 2021, to meet Nasdaq's minimum bid price compliance requirement. The company aims to achieve compliance either through stock price growth or a proposed reverse stock split, with a ratio between 1-for-5 and 1-for-20. Avinger's management urges shareholders to vote FOR this proposal during the December 10 annual meeting. The company highlighted progress in 2020, including FDA clearance of new products and a strong balance sheet, positioning Avinger for growth despite challenges posed by the COVID-19 pandemic.

Avinger, Inc. (NASDAQ:AVGR) has launched its Lumivascular products in Israel, marking its entry into the Israeli healthcare market. The company signed an exclusive distribution agreement with Neopharm Medical Supplies for its Pantheris atherectomy and Ocelot CTO devices. Regulatory registration was completed in July, with initial patient cases successfully carried out in October. Avinger's CEO emphasized the advancement in treating Peripheral Artery Disease (PAD) through the unique imaging capability of their devices, aiming to reduce complications compared to traditional therapies.

Avinger, Inc. (NASDAQ:AVGR) will release its Q3 2020 financial results on November 10, 2020, after market close. A conference call is scheduled for 1:30 PM PT (4:30 PM ET) where details will be discussed. Avinger specializes in catheter-based systems for diagnosing and treating Peripheral Artery Disease (PAD), impacting over 12 million people in the U.S. The company aims to transform vascular disease treatment through its Lumivascular platform. A live webcast will be available on their investor relations page.

Avinger, Inc. (NASDAQ:AVGR) has announced that physicians in three U.S. centers successfully treated patients using the TIGEREYE™ image-guided chronic total occlusion (CTO) crossing system. The device, part of a limited launch at up to 10 top clinical sites, offers enhanced imaging and steerability, promising improved outcomes for patients with Peripheral Artery Disease (PAD). Avinger anticipates a full commercial rollout in Q1 2021, aiming to significantly expand their position in the CTO segment.

Avinger, Inc. (NASDAQ:AVGR) announced FDA clearance for its TIGEREYE system, an innovative next-generation image-guided chronic total occlusion (CTO) crossing device. This launch, expected in early 2021, enhances the company's offerings in treating Peripheral Artery Disease with real-time imaging capabilities. CEO Jeff Soinski emphasized TIGEREYE's potential to drive growth in their CTO-crossing business, bolstered by a robust financial position with over $25 million in cash. This advancement follows the company's recent product launches and seeks to expand their market presence.

Avinger, Inc. (NASDAQ:AVGR) has announced the full exercise of the underwriter's option to purchase an additional 1,000,000 shares of common stock at $0.47 per share. This results in total gross proceeds of approximately $5.67 million, before any deductions. The offering was made under a previously filed shelf registration statement with the SEC. Aegis Capital Corp. acted as the sole bookrunner for this offering. Avinger, which focuses on innovative treatment solutions for Peripheral Artery Disease (PAD), remains committed to advancing its Lumivascular platform.

Aegis Capital Corp. has acted as the Sole Bookrunner for a $5.2 million follow-on offering for Avinger Inc. (NASDAQ:AVGR). Avinger is a medical device company focusing on image-guided systems for the diagnosis and treatment of Peripheral Artery Disease (PAD), which affects over 12 million people in the U.S. Avinger's Lumivascular platform comprises the Lightbox imaging console, Ocelot CTO catheters, and Pantheris atherectomy devices, aiming to revolutionize vascular disease treatment.

Avinger, Inc. (NASDAQ: AVGR) announced the closing of an underwritten public offering of 11,063,830 shares of common stock at $0.47 per share, resulting in gross proceeds of approximately $5.2 million. An additional 1,000,000 shares may be purchased by underwriters for overallotments. These shares were offered under a previously filed shelf registration statement with the SEC. The proceeds aim to support the development of Avinger’s Lumivascular platform, designed for treating Peripheral Artery Disease (PAD).

Avinger, Inc. (NASDAQ:AVGR) announced that underwriters exercised their option to purchase an additional 2,368,421 shares at $0.38 per share, raising total gross proceeds to approximately $6.9 million. This follows a prior underwritten public offering. The shares were offered under a shelf registration declared effective by the SEC. Aegis Capital Corp. served as the sole bookrunner. Avinger is committed to innovating treatment for Peripheral Artery Disease (PAD), affecting over 12 million people in the U.S.